SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-005292
Filing Date
2020-05-06
Accepted
2020-05-06 08:01:17
Documents
62
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sbbp-20200331x10q.htm 10-Q 1323264
2 EX-31.1 sbbp-20200331ex311d3af15.htm EX-31.1 17567
3 EX-31.2 sbbp-20200331ex3120e48e6.htm EX-31.2 17569
4 EX-32.1 sbbp-20200331ex321f19183.htm EX-32.1 17597
  Complete submission text file 0001558370-20-005292.txt   4991563

Data Files

Seq Description Document Type Size
5 EX-101.INS sbbp-20200331.xml EX-101.INS 985086
6 EX-101.SCH sbbp-20200331.xsd EX-101.SCH 39889
7 EX-101.CAL sbbp-20200331_cal.xml EX-101.CAL 44273
8 EX-101.DEF sbbp-20200331_def.xml EX-101.DEF 128586
9 EX-101.LAB sbbp-20200331_lab.xml EX-101.LAB 394050
10 EX-101.PRE sbbp-20200331_pre.xml EX-101.PRE 271251
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

IRS No.: 981130690 | State of Incorp.: L2
Type: 10-Q | Act: 34 | File No.: 001-37569 | Film No.: 20851193
SIC: 2834 Pharmaceutical Preparations